모바일릴게임접속하기 77.ryn949.top 우주전함야마토2202 > 절개헤어라인교정 - 여성헤어라인교정

• 목록
• 답변
• 글쓰기

체리마스터 확률 19.ryn949.top 바로가기 야마토릴게임, 황금성연타

무료인터넷게임릴게임추천사이트슬롯머신무료잭팟

릴게임검증 65.ryn949.top 슬롯버그

블랙홀3D 릴게임 80.ryn949.top 바다이야기하는법

릴게임연타 23.ryn949.top 한게임바둑이게임

바다신 게임 21.ryn949.top 야마토오락실게임

릴게임뽀빠이 42.ryn949.top 신오션파라다이스

모바일오션파라다이스7 69.ryn949.top 슬롯머신 이기는 방법

릴게임 59.ryn949.top 릴게임사이다

황금성용가리 17.ryn949.top 황금성게임다운로드후기

바다신2영상 71.ryn949.top 슬롯머신 무료체험

고전릴게임 54.ryn949.top 인터넷야마토

황금성제주도 바다이야기 황금고래 야마토게임 다운로드 오션파라 다이스하는방법 바다이야기고래 먹튀피해복구 최신바다이야기게임 바다이야기 황금고래 바다이야기조작 오션슬롯주소 일본 야마토 게임 황금성온라인 신천지릴게임장주소 슬롯머신 이기는 방법 황금성3 사설배팅 릴게임총판 강원랜드 슬롯머신 추천 슬롯사이트 로드할 바다이야기넥슨 슬롯무료게임 황금성배당 황금성게임장 릴게임주소 꽁머니사이트 88오락실릴게임 무료충전 바다이야기 황금성게임다운로드후기 도그하우스 하는법 프라그마틱 슬롯 팁 카지노 슬롯 게임 추천 야마토3동영상 바다이야기 예시 무료충전 바다이야기 바다이야기 파칭코 슬롯머신무료 사다리게임주소 도그하우스 하는법 88오락실릴게임 성인놀이터 온라인신천지게임 카지노 슬롯머신 잭팟 야마토게임 기 슬롯종류 올쌈바 바다이야기환전 오션파라다이스릴게임 황금성게임종류 바둑이넷마블 온라인게임 바다신2 게임 릴게임놀이터 인터넷 바다이야기 릴게임뽀빠이 야마토 무료 게임 파칭코게임 프라그마틱환수율 무료머니릴게임 우주전함 야마토 2199 모바일릴게임 종류 카지노 슬롯 게임 추천 슬롯머신무료 바다이야기 파칭코 일본빠징고 황금포카성 프라그마틱 무료체험 메타 릴신천지 뽀빠이놀이터릴게임 알라딘 프라그마틱 슬롯 조작 릴게임백경 황금성게임예시 인터넷야마토게임 야마토무료게임 슬롯머신 잭팟 종류 일본경륜 바다이야기 모바일게임 릴게임야마토 야마토 2 온라인 게임 신천지게임 하는곳 야마토게임장주소 빠찡코 하는 방법 알라딘게임잭팟 바다이야기 확률 카지노 슬롯머신 종류 온라인 릴게임 프라그마틱 슬롯 종류 바다이야기꽁머니 신규릴게임 오션파라다이스 다운로드 메이저 슬롯사이트 빠칭코 손오공 바다이야기 파일 양귀비 릴게임 황금성3게임다운로드 슬롯머신 영어로 인터넷야마토주소 일본야마토 릴게임5만릴짱 오션파라다이스게임다운로드 유희왕 황금성 바다이야기 온라인 릴게임다운로드 황금성 게임 바다이야기 게임기 바다이야기 사이트 강원랜드 슬롯머신 하는법 슬롯총판 캡틴프라이드게임 카카오야마토먹튀 강원랜드 슬롯머신 가격 우주전함 야마토 2202 릴게임오션 온라인야마토 스위피릴게임 바다이야기 먹튀 신고 황금성연타 PC 릴게임 릴게임무료 황금성게임후기 바다이야기파일 바다이야기 슬롯 무료인터넷바다이야기 This article was released as Pharm Edaily Premium Content on May 27, 2025, at 7:35 AM.


[Shin-Min Joon, Edaily Reporter] On May 26 the Korean pharmaceutical and biotech market saw sharp rallies in the share prices of Raphas, Daewhapharmand Cellumed. Raphas surged on news of progress in its microneedle based obesity patch. Daewhapharm gained after announcing that Pha 신탁등기 se 3 clinical trial results for its oral cancer drug Liporaxel were selected for presentation at a major global oncology congress. Cellumed’s rally was driven by expectations of improved earnings from 제1금융기관 strong sales of its dental bone graft products. ·



Raphas stock trend on May 26. (Image=MP Doctor)



Raphas So 수협 정기예금 ars on Obesity Patch Clinical Results

According to MP DOCTOR (formerly MarketPoint) by KG Zeroin Raphas shares jumped 29.75% to close at won 21,150, hitting the upper trading limi 아르바이트 유급휴가 t early in the session. Raphas, in partnership with Daewon Pharmaceutical, is developing DW1022, a microneedle patch version of semaglutide, the active ingredient in blockbuster obesity drug Wegovy. T 인터넷대출신청 his marks the world’s first attempt to develop an obesity treatment patch using microneedle technology.
Raphas completed a Phase 1 clinical trial of DW1022 at the end of last year. The results showed a bioavailability approximately 30% higher than that of subcutaneous injections. Considering that the oral semaglutide (Rybelsus by Novo Nordisk) has a bioavailability of less than 0.5% compared to subcutaneous injections, DW1022 achieves nearly 60 times greater absorption efficiency.
The Phase 1 study also confirmed the drug’s pharmacokinetics tolerability and safety after a single daily application. Raphas plans to conduct further trials to evaluate repeated dose weight loss efficacy and pharmacokinetics at higher concentrations. The company is also exploring a once weekly formulation that could maintain efficacy with weekly application. To date, no microneedle based prescription drug has been commercialized globally.
Beyond the obesity patch Raphas is developing other microneedle based products. The company recently launched Reti-RN, the world’s first patch combining retinol and polydeoxyribonucleotide (PDRN) in a stable formulation. Retinol is known for its anti-aging effects, while PDRN, extracted from salmon DNA, promotes skin regeneration and elasticity. Raphas is also working on a hepatitis B vaccine patch using microneedle technology.
A Raphas spokesperson commented “Our microneedle based obesity patch development is progressing smoothly and we are committed to ensuring its timely development.”
DaewhapharmRises on Global Cancer Conference Presentation
Daewhapharmshares climbed 9.96% to won 15,020, buoyed by the news that its Liporaxel data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, one of the world’s three largest oncology conferences, scheduled from May 30 to June 3 in Chicago.
Liporaxel is an oral formulation and improved version of Taxol (paclitaxel), a blockbuster intravenous anticancer drug developed by Bristol Myers Squibb that has been in use for over 30 years. Daewhapharmis expanding Liporaxel’s indications from gastric cancer to recurrent and metastatic breast cancer.
In results received earlier this year from a contract research organization (CRO), Liporaxel demonstrated non-inferior efficacy and safety compared to IV paclitaxel in a multinational Phase 2/3 trial involving 582 patients (33 in Phase 2 and 549 in Phase 3). The Phase 2 trial was conducted at 12 sites in Korea, and the Phase 3 trial at 51 sites across Korea, China, Hungary, Serbia, and Bulgaria.
For the primary endpoint of progression free survival (PFS) in the per-protocol set (PPS), Liporaxel achieved a median PFS of 10.02 months, compared to 8.54 months for the IV formulation. Secondary endpoints such as overall survival (OS), objective response rate (ORR), and disease control rate (DCR) also showed trends of non inferiority.
In terms of safety, the incidence rates of treatment emergent adverse events (TEAEs) and adverse drug reactions (ADRs) were comparable between the oral and injectable forms. Liporaxel is currently being marketed in China through local partner Haihe Biopharma and distributor 3S BIO. Daewhapharmalso plans to expand into the transdermal drug delivery system (TDDS) market with products such as dermal fillers and dementia patches.
A company representative noted “News of our abstract selection at ASCO appears to have positively influenced our stock performance.”
Cellumed Advances on Strong Sales of Dental Bone Graft
Cellumed shares rose 10.33% to won 961, driven by strong sales of its Rafugen Dental graft, a high performance bone graft product used in dental implants to restore bone defects.
Cellumed recently doubled its production capacity through process improvements and expanded its global raw material supply chain to ensure a stable manufacturing system. This enables the company to respond quickly to growing demand.
The growth of the Korean dental implant market supports this trend. According to data from the Health Insurance Review and Assessment Service, the number of dental implant patients rose from 719,309 in 2020 to 837,634 in 2023 a 16% increase reflecting the aging population and heightened awareness of oral health.
In 2024 Cellumed posted won 129.1 billion in revenue up 35% year on year and narrowed its operating loss to won 6.8 billion from won 10.5 billion. The company is actively strengthening its global raw material supply through partnerships with overseas firms to ensure stable production of its core bone regeneration and skin graft products.
A company official stated “Demand for Rafugen Dental is surging in clinical settings, particularly in the Seoul metropolitan area. The product has received favorable reviews, and we continue to receive requests for increased supply.”
The spokesperson added “Cellumed is aggressively marketing to make the dental sector a core business. We aim to expand our market share through stable supply, technological strength, and the launch of new high-efficacy products.”
신민준 (adonis@edaily.co.kr)